1. Targeted compounds exhibit cancer-selective ex vivo drug responses in AML. A, waterfall plot that highlights the most potent cancer-selective drugs for each individual patient as well as drugs that are most likely to exhibit resistance/no sensitivity.
Targeted compounds exhibit cancer-selective ex vivo drug responses in AML. A, waterfall plot that highlights the most potent cancer-selective drugs for each individual patient as well as drugs that are most likely to exhibit resistance/no sensitivity. B, comparison of cancer selectivity of ex vivo drug responses (DSS) of four clinically approved drugs, conventional chemotherapeutic agents (left), and four signal transduction inhibitors (right). The DSSs are compared between healthy bone marrow samples (controls; n = 7) and AML patient samples (n = 28) with the range and median DSS value depicted. C and D, the distribution of the sensitivity to trametinib (MEK inhibitor) and idarubicin (topoisomerase II inhibitor) in 28 AML patient and 7 control samples expressed as Z-score (SD from the average control DSS drug response). E, percentages of AML patient samples selectively responding ex vivo to selected signal transduction inhibitors as assessed by sDSS, represented as a bar graph.
Tea Pemovska et al. Cancer Discovery 2013;3:
©2013 by American Association for Cancer Research